Vanda Pharmaceuticals Inc.VNDANASDAQ
LOADING
|||
Switch Symbol:
Net Income Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year net income growth rate
Latest
16.98%
↓ 24% below average
Average (39q)
22.23%
Historical baseline
Range
High:1983.33%
Low:-1851.82%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 16.98% |
| Q2 2025 | 7.75% |
| Q1 2025 | -500.45% |
| Q4 2024 | 7.74% |
| Q3 2024 | -17.84% |
| Q2 2024 | -8.97% |
| Q1 2024 | -72.75% |
| Q4 2023 | -1851.82% |
| Q3 2023 | -90.99% |
| Q2 2023 | -53.26% |
| Q1 2023 | -52.60% |
| Q4 2022 | 109.82% |
| Q3 2022 | 27.04% |
| Q2 2022 | 140.03% |
| Q1 2022 | -190.84% |
| Q4 2021 | -8.92% |
| Q3 2021 | -19.50% |
| Q2 2021 | 11.60% |
| Q1 2021 | 5.62% |
| Q4 2020 | 37.72% |
| Q3 2020 | -31.75% |
| Q2 2020 | 1693.00% |
| Q1 2020 | -88.47% |
| Q4 2019 | -95.80% |
| Q3 2019 | 771.27% |
| Q2 2019 | 1983.33% |
| Q1 2019 | -105.91% |
| Q4 2018 | 44.47% |
| Q3 2018 | 55.52% |
| Q2 2018 | 50.39% |
| Q1 2018 | 266.81% |
| Q4 2017 | 59.60% |
| Q3 2017 | -196.61% |
| Q2 2017 | 79.93% |
| Q1 2017 | -1165.73% |
| Q4 2016 | -40.47% |
| Q3 2016 | 90.69% |
| Q2 2016 | 62.63% |
| Q1 2016 | 16.49% |
| Q4 2015 | -56.41% |